Price Change to Note: Can CorMedix Inc.’s Tomorrow be Different? The Stock Declines Again

Price Change to Note: Can CorMedix Inc.'s Tomorrow be Different? The Stock Declines Again

The stock of CorMedix Inc. (NYSEMKT:CRMD) is a huge mover today! About 497,132 shares traded hands. CorMedix Inc. (NYSEMKT:CRMD) has risen 35.98% since March 3, 2016 and is uptrending. It has outperformed by 27.64% the S&P500.
The move comes after 6 months negative chart setup for the $134.15 million company. It was reported on Oct, 6 by We have $2.66 PT which if reached, will make NYSEMKT:CRMD worth $16.10 million less.

Analysts await CorMedix Inc. (NYSEMKT:CRMD) to report earnings on November, 10. They expect $-0.15 earnings per share, down 7.14% or $0.01 from last year’s $-0.14 per share. After $-0.13 actual earnings per share reported by CorMedix Inc. for the previous quarter, Wall Street now forecasts 15.38% negative EPS growth.

According to Zacks Investment Research, “CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey.”

Insitutional Activity: The institutional sentiment decreased to 0.54 in Q2 2016. Its down 1.10, from 1.64 in 2016Q1. The ratio is negative, as 18 funds sold all CorMedix Inc. shares owned while 17 reduced positions. 10 funds bought stakes while 9 increased positions. They now own 4.22 million shares or 33.14% less from 6.32 million shares in 2016Q1.
Envestnet Asset Inc holds 2,000 shares or 0% of its portfolio. The Texas-based Ray Gerald L Ltd has invested 0.04% in CorMedix Inc. (NYSEMKT:CRMD). National Bank Of America Corporation De has invested 0% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD). Bollard Lc has 0.07% invested in the company for 511,077 shares. The California-based Blackrock Institutional Tru Co Na has invested 0% in CorMedix Inc. (NYSEMKT:CRMD). Vanguard Gru accumulated 0% or 1.11M shares. Lmr Partners Llp last reported 45,320 shares in the company. Moreover, Susquehanna Int Gru Ltd Liability Partnership has 0% invested in CorMedix Inc. (NYSEMKT:CRMD) for 45,329 shares. Paloma Mngmt owns 132,864 shares or 0% of their US portfolio. Tower Rech Capital Ltd Liability Co (Trc) accumulated 2,394 shares or 0% of the stock. Dimensional Fund Ltd Partnership reported 10,258 shares or 0% of all its holdings. The Arizona-based Tci Wealth Advsr has invested 0.01% in CorMedix Inc. (NYSEMKT:CRMD). Citigroup last reported 0% of its portfolio in the stock. Commonwealth Equity reported 10,091 shares or 0% of all its holdings. Moreover, Blackrock Fund Advsr has 0% invested in CorMedix Inc. (NYSEMKT:CRMD) for 88,066 shares.

Insider Transactions: Since May 18, 2016, the stock had 4 insider purchases, and 9 selling transactions for $406,065 net activity. $34,656 worth of shares were sold by Pfaffle Antony on Tuesday, May 24. 12,500 shares with value of $21,588 were bought by TELLEZ CORA M on Friday, August 19. Lefkowitz Steven W also sold $87,958 worth of CorMedix Inc. (NYSEMKT:CRMD) on Friday, May 20. $126,008 worth of CorMedix Inc. (NYSEMKT:CRMD) shares were sold by Duffy Matthew. $30,690 worth of CorMedix Inc. (NYSEMKT:CRMD) was bought by Markvicka Taunia on Thursday, August 25. $34,496 worth of CorMedix Inc. (NYSEMKT:CRMD) was bought by Kaplan Myron.

More news for CorMedix Inc. (NYSEMKT:CRMD) were recently published by:, which released: “Resonant Down 70%… Could CorMedix Inc. (CRMD) Be Next?” on April 13, 2015.‘s article titled: “CorMedix, Inc. Announces Signing of an Agreement with POETIC (Pediatric …” and published on September 15, 2016 is yet another important article.

CRMD Company Profile

CorMedix Inc., incorporated on July 28, 2006, is a commercial pharmaceutical and medical device company. The Firm in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Firm has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment